7-octadecynoic acid

7-octadecynoic acid is a lipid of Fatty Acyls (FA) class.

Cross Reference

There are no associated biomedical information in the current reference collection.

Current reference collection contains 19785 references associated with 7-octadecynoic acid in LipidPedia. Due to lack of full text of references or no associated biomedical terms are recognized in our current text-mining method, we cannot extract any biomedical terms related to diseases, pathways, locations, functions, genes, lipids, and animal models from the associated reference collection.

Users can download the reference list at the bottom of this page and read the reference manually to find out biomedical information.


Here are additional resources we collected from PubChem and MeSH for 7-octadecynoic acid

Possible diseases from mapped MeSH terms on references

We collected disease MeSH terms mapped to the references associated with 7-octadecynoic acid

MeSH term MeSH ID Detail
Angioid Streaks D000793 1 associated lipids
Ankylosis D000844 1 associated lipids
Aortic Diseases D001018 11 associated lipids
Arteriosclerosis D001161 86 associated lipids
Arthritis D001168 41 associated lipids
Arthritis, Experimental D001169 24 associated lipids
Arthritis, Rheumatoid D001172 3 associated lipids
Arthropathy, Neurogenic D001177 1 associated lipids
Atrial Fibrillation D001281 16 associated lipids
Autoimmune Diseases D001327 27 associated lipids
Per page 10 20 50 100 | Total 298

All references with 7-octadecynoic acid

Download all related citations
Per page 10 20 50 100 | Total 4091
Authors Title Published Journal PubMed Link
Petersson M et al. Oxytocin stimulates proliferation of human osteoblast-like cells. 2002 Peptides pmid:12126740
Cundy T et al. A mutation in the gene TNFRSF11B encoding osteoprotegerin causes an idiopathic hyperphosphatasia phenotype. 2002 Hum. Mol. Genet. pmid:12189164
Lee SK et al. 1,25(OH)2 vitamin D3-stimulated osteoclast formation in spleen-osteoblast cocultures is mediated in part by enhanced IL-1 alpha and receptor activator of NF-kappa B ligand production in osteoblasts. 2002 J. Immunol. pmid:12193704
Chen XW et al. Isoflavones regulate interleukin-6 and osteoprotegerin synthesis during osteoblast cell differentiation via an estrogen-receptor-dependent pathway. 2002 Biochem. Biophys. Res. Commun. pmid:12150965
Katagiri T and Takahashi N Regulatory mechanisms of osteoblast and osteoclast differentiation. 2002 Oral Dis pmid:12108759
Granchi D et al. Bone cement extracts modulate the osteoprotegerin/osteoprotegerin-ligand expression in MG63 osteoblast-like cells. 2002 Biomaterials pmid:12013183
Li X et al. Prostaglandin receptor EP2 mediates PGE2 stimulated hypercalcemia in mice in vivo. 2002 Prostaglandins Other Lipid Mediat. pmid:12013525
Bosshart H Expression of survival receptors in Hodgkin disease cell lines. 2002 Blood pmid:12001908
Ono K et al. Involvement of cyclo-oxygenase-2 in osteoclast formation and bone destruction in bone metastasis of mammary carcinoma cell lines. 2002 J. Bone Miner. Res. pmid:12009007
Fu Q et al. Parathyroid hormone stimulates receptor activator of NFkappa B ligand and inhibits osteoprotegerin expression via protein kinase A activation of cAMP-response element-binding protein. 2002 J. Biol. Chem. pmid:12364326
Rogers A et al. Circulating estradiol and osteoprotegerin as determinants of bone turnover and bone density in postmenopausal women. 2002 J. Clin. Endocrinol. Metab. pmid:12364420
Romas E et al. Osteoprotegerin reduces osteoclast numbers and prevents bone erosion in collagen-induced arthritis. 2002 Am. J. Pathol. pmid:12368214
Standal T et al. Osteoprotegerin is bound, internalized, and degraded by multiple myeloma cells. 2002 Blood pmid:12351414
Biskobing DM et al. Novel therapeutic options for osteoporosis. 2002 Curr Opin Rheumatol pmid:12118183
Mizukami J et al. Receptor activator of NF-kappaB ligand (RANKL) activates TAK1 mitogen-activated protein kinase kinase kinase through a signaling complex containing RANK, TAB2, and TRAF6. 2002 Mol. Cell. Biol. pmid:11809792
Shiotani A et al. Regulation of osteoclast differentiation and function by receptor activator of NFkB ligand and osteoprotegerin. 2002 Anat. Rec. pmid:12221720
Cremer I et al. Long-lived immature dendritic cells mediated by TRANCE-RANK interaction. 2002 Blood pmid:12393586
Giuliani N et al. Human myeloma cells stimulate the receptor activator of nuclear factor-kappa B ligand (RANKL) in T lymphocytes: a potential role in multiple myeloma bone disease. 2002 Blood pmid:12393684
Liao EY et al. Comparison of the effects of 17beta-E2 and progesterone on the expression of osteoprotegerin in normal human osteoblast-like cells. 2002 J. Endocrinol. Invest. pmid:12398237
Haas M et al. Osteoprotegerin and parathyroid hormone as markers of high-turnover osteodystrophy and decreased bone mineralization in hemodialysis patients. 2002 Am. J. Kidney Dis. pmid:11877577
Goater JJ et al. Efficacy of ex vivo OPG gene therapy in preventing wear debris induced osteolysis. 2002 J. Orthop. Res. pmid:11918293
Roux S et al. RANK (receptor activator of nuclear factor-kappaB) and RANKL expression in multiple myeloma. 2002 Br. J. Haematol. pmid:11918537
Oshiro T et al. Osteoclast induction in periodontal tissue during experimental movement of incisors in osteoprotegerin-deficient mice. 2002 Anat. Rec. pmid:11920384
Hasegawa T et al. Expression of receptor activator of NF-kappa B ligand and osteoprotegerin in culture of human periodontal ligament cells. 2002 J. Periodont. Res. pmid:12472833
Yamashita T et al. Double mutations in klotho and osteoprotegerin gene loci rescued osteopetrotic phenotype. 2002 Endocrinology pmid:12446599
Saidenberg Kermanac'h N et al. Osteoprotegerin and inflammation. 2002 Apr-Jun Eur. Cytokine Netw. pmid:12101070
Jung K et al. Osteoprotegerin and receptor activator of nuclear factor-kappaB ligand (RANKL) in the serum of healthy adults. 2002 Jul-Sep Int. J. Biol. Markers pmid:12408468
Stilgren LS et al. Osteoprotegerin levels in primary hyperparathyroidism: effect of parathyroidectomy and association with bone metabolism. 2003 Calcif. Tissue Int. pmid:14667132
Okada T et al. Bone marrow metastatic myeloma cells promote osteoclastogenesis through RANKL on endothelial cells. 2003 Clin. Exp. Metastasis pmid:14669795
Gannagé-Yared MH et al. Effects of a short-term calcium and vitamin D treatment on serum cytokines, bone markers, insulin and lipid concentrations in healthy post-menopausal women. 2003 J. Endocrinol. Invest. pmid:14669830
Ashcroft AJ et al. Colonic dendritic cells, intestinal inflammation, and T cell-mediated bone destruction are modulated by recombinant osteoprotegerin. 2003 Immunity pmid:14670302
Min JK et al. Vascular endothelial growth factor up-regulates expression of receptor activator of NF-kappa B (RANK) in endothelial cells. Concomitant increase of angiogenic responses to RANK ligand. 2003 J. Biol. Chem. pmid:12893832
Chong B et al. Idiopathic hyperphosphatasia and TNFRSF11B mutations: relationships between phenotype and genotype. 2003 J. Bone Miner. Res. pmid:14672344
Teitelbaum SL and Ross FP Genetic regulation of osteoclast development and function. 2003 Nat. Rev. Genet. pmid:12897775
Nielsen KL et al. Biglycan deficiency interferes with ovariectomy-induced bone loss. 2003 J. Bone Miner. Res. pmid:14672350
Si AI et al. Expression and localization of extracellular matrix metalloproteinase inducer in giant cell tumor of bone. 2003 J. Cell. Biochem. pmid:12898514
Nitta K et al. The progression of vascular calcification and serum osteoprotegerin levels in patients on long-term hemodialysis. 2003 Am. J. Kidney Dis. pmid:12900812
Amizuka N et al. Defective bone remodelling in osteoprotegerin-deficient mice. 2003 J Electron Microsc (Tokyo) pmid:14756238
Fizazi K et al. Prostate cancer cells-osteoblast interaction shifts expression of growth/survival-related genes in prostate cancer and reduces expression of osteoprotegerin in osteoblasts. 2003 Clin. Cancer Res. pmid:12855635
Kawana F and Sasaki T Osteoclast differentiation and characteristic trabecular bone formation during growth plate destruction in osteoprotegerin-deficient mice. 2003 J Electron Microsc (Tokyo) pmid:14756239
Okuma K et al. Development of a novel surrogate virus for human T-cell leukemia virus type 1: inhibition of infection by osteoprotegerin. 2003 J. Virol. pmid:12857926
Cheng X et al. The TNF receptor superfamily: role in immune inflammation and bone formation. 2003 Immunol. Res. pmid:12857975
Shin MM et al. High extracellular Ca2+ alone stimulates osteoclast formation but inhibits in the presence of other osteoclastogenic factors. 2003 Exp. Mol. Med. pmid:12858015
Glossop JR et al. No association of polymorphisms in the tumor necrosis factor receptor I and receptor II genes with disease severity in rheumatoid arthritis. 2003 J. Rheumatol. pmid:12858434
Hampson G et al. Effects of dietary improvement on bone metabolism in elderly underweight women with osteoporosis: a randomised controlled trial. 2003 Osteoporos Int pmid:12904840
Misra M et al. Serum osteoprotegerin in adolescent girls with anorexia nervosa. 2003 J. Clin. Endocrinol. Metab. pmid:12915674
Lonergan M et al. Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL), TRAIL receptors, and the soluble receptor osteoprotegerin in human gestational membranes and amniotic fluid during pregnancy and labor at term and preterm. 2003 J. Clin. Endocrinol. Metab. pmid:12915677
Abrahamsen B et al. Effects of the natural and artificial menstrual cycle on the production of osteoprotegerin and the bone resorptive cytokines IL-1beta and IL-6. 2003 Calcif. Tissue Int. pmid:12384814
Sezer O et al. RANK ligand and osteoprotegerin in myeloma bone disease. 2003 Blood pmid:12424190
Yamada T et al. Regulation of osteoclast development by Notch signaling directed to osteoclast precursors and through stromal cells. 2003 Blood pmid:12411305
Smith MD et al. Microarchitecture and protective mechanisms in synovial tissue from clinically and arthroscopically normal knee joints. 2003 Ann. Rheum. Dis. pmid:12634226
Sakurai A et al. Streptococcus pyogenes infection induces septic arthritis with increased production of the receptor activator of the NF-kappaB ligand. 2003 Infect. Immun. pmid:14500523
Kim HH et al. RANKL regulates endothelial cell survival through the phosphatidylinositol 3'-kinase/Akt signal transduction pathway. 2003 FASEB J. pmid:14500543
Nakamura M et al. Osteoprotegerin regulates bone formation through a coupling mechanism with bone resorption. 2003 Endocrinology pmid:14500574
Zhang Z et al. Receptor activator of NF-kappa B ligand stimulates recruitment of SHP-1 to the complex containing TNFR-associated factor 6 that regulates osteoclastogenesis. 2003 J. Immunol. pmid:14500659
Ueno Y et al. In vivo administration of 1,25-dihydroxyvitamin D3 suppresses the expression of RANKL mRNA in bone of thyroparathyroidectomized rats constantly infused with PTH. 2003 J. Cell. Biochem. pmid:14505343
Kaneyama K et al. Osteoclastogenesis inhibitory factor/osteoprotegerin in synovial fluid from patients with temporomandibular disorders. 2003 Int J Oral Maxillofac Surg pmid:14505625
Grigorie D et al. Circulating osteoprotegerin and leptin levels in postmenopausal women with and without osteoporosis. 2003 Rom J Intern Med pmid:15526523
Ha H et al. Membrane rafts play a crucial role in receptor activator of nuclear factor kappaB signaling and osteoclast function. 2003 J. Biol. Chem. pmid:12637570
Ritchlin CT et al. Mechanisms of TNF-alpha- and RANKL-mediated osteoclastogenesis and bone resorption in psoriatic arthritis. 2003 J. Clin. Invest. pmid:12639988
Kido S et al. Expression of RANK is dependent upon differentiation into the macrophage/osteoclast lineage: induction by 1alpha,25-dihydroxyvitamin D3 and TPA in a human myelomonocytic cell line, HL60. 2003 Bone pmid:12810169
Kudlacek S et al. Serum levels of osteoprotegerin increase with age in a healthy adult population. 2003 Bone pmid:12810175
Mandelin J et al. Imbalance of RANKL/RANK/OPG system in interface tissue in loosening of total hip replacement. 2003 J Bone Joint Surg Br pmid:14653607
Ikeda T et al. Hepatocellular carcinoma with osteoclast-like giant cells: possibility of osteoclastogenesis by hepatocyte-derived cells. 2003 Pathol. Int. pmid:12828610
Malyszko J et al. Osteoprotegerin and its correlations with new markers of bone formation and bone resorption in kidney transplant recipients. 2003 Transplant. Proc. pmid:14529897
Crotti T et al. Receptor activator NF kappaB ligand (RANKL) and osteoprotegerin (OPG) protein expression in periodontitis. 2003 J. Periodont. Res. pmid:12828654
Ren W et al. Distinct gene expression of receptor activator of nuclear factor-kappaB and rank ligand in the inflammatory response to variant morphologies of UHMWPE particles. 2003 Biomaterials pmid:14530078
Tazoe M et al. Involvement of p38MAP kinase in bone morphogenetic protein-4-induced osteoprotegerin in mouse bone-marrow-derived stromal cells. 2003 Arch. Oral Biol. pmid:12828991
Wiethe C et al. Enhanced effector and memory CTL responses generated by incorporation of receptor activator of NF-kappa B (RANK)/RANK ligand costimulatory molecules into dendritic cell immunogens expressing a human tumor-specific antigen. 2003 J. Immunol. pmid:14530334
Wiethe C et al. Provision of 4-1BB ligand enhances effector and memory CTL responses generated by immunization with dendritic cells expressing a human tumor-associated antigen. 2003 J. Immunol. pmid:12626542
Wagner EF and Matsuo K Signalling in osteoclasts and the role of Fos/AP1 proteins. 2003 Ann. Rheum. Dis. pmid:14532157
Ueland T et al. Age-related changes in cortical bone content of insulin-like growth factor binding protein (IGFBP)-3, IGFBP-5, osteoprotegerin, and calcium in postmenopausal osteoporosis: a cross-sectional study. 2003 J. Clin. Endocrinol. Metab. pmid:12629078
Ueland T et al. Growth hormone substitution increases gene expression of members of the IGF family in cortical bone from women with adult onset growth hormone deficiency--relationship with bone turn-over. 2003 Bone pmid:14555269
Schoppet M et al. Increased osteoprotegerin serum levels in men with coronary artery disease. 2003 J. Clin. Endocrinol. Metab. pmid:12629080
Nagata N et al. Inhibition of RANKL-induced osteoclast formation in mouse bone marrow cells by IL-12: involvement of IFN-gamma possibly induced from non-T cell population. 2003 Bone pmid:14555278
Han W et al. Construction of a new tumour necrosis factor fusion-protein expression vector for high-level expression of heterologous genes in Escherichia coli. 2003 Biotechnol. Appl. Biochem. pmid:12630898
Grimaud E et al. Receptor activator of nuclear factor kappaB ligand (RANKL)/osteoprotegerin (OPG) ratio is increased in severe osteolysis. 2003 Am. J. Pathol. pmid:14578201
Coen G et al. Serum leptin in dialysis renal osteodystrophy. 2003 Am. J. Kidney Dis. pmid:14582047
Yorke R et al. Receptor activator of nuclear factor kappaB (RANK) is expressed as a late event during malignant progression in Barrett's metaplasia. 2003 Eur. J. Cancer pmid:12957466
Kaneyama K et al. Expression of osteoprotegerin in synovial tissue and degradation of articular cartilage: comparison with arthroscopic findings of temporomandibular joint disorders. 2003 Oral Surg Oral Med Oral Pathol Oral Radiol Endod pmid:12973279
Lee ZH and Kim HH Signal transduction by receptor activator of nuclear factor kappa B in osteoclasts. 2003 Biochem. Biophys. Res. Commun. pmid:12745060
Boyle WJ et al. Osteoclast differentiation and activation. 2003 Nature pmid:12748652
Terpos E et al. Soluble receptor activator of nuclear factor kappaB ligand-osteoprotegerin ratio predicts survival in multiple myeloma: proposal for a novel prognostic index. 2003 Blood pmid:12689925
Zheng B et al. MEK/ERK pathway is aberrantly active in Hodgkin disease: a signaling pathway shared by CD30, CD40, and RANK that regulates cell proliferation and survival. 2003 Blood pmid:12689928
Moreno JL et al. IL-4 suppresses osteoclast development and mature osteoclast function by a STAT6-dependent mechanism: irreversible inhibition of the differentiation program activated by RANKL. 2003 Blood pmid:12689929
Dovio A et al. Autocrine down-regulation of glucocorticoid receptors by interleukin-11 in human osteoblast-like cell lines. 2003 J. Endocrinol. pmid:12697042
Nakano M et al. Inhibitory effect of titanium particles on osteoclast formation generated by treatment of mouse bone marrow cells with PGE2. 2003 Oral Dis pmid:12657033
Ra JS et al. Osteoprotegerin inhibits proliferation of myeloid progenitor cells. 2003 J. Hematother. Stem Cell Res. pmid:12662434
Szalay F et al. High serum osteoprotegerin and low RANKL in primary biliary cirrhosis. 2003 J. Hepatol. pmid:12663228
Kato I et al. TRANCE together with IL-7 induces pre-B cells to proliferate. 2003 Eur. J. Immunol. pmid:12548564
Sordillo EM and Pearse RN RANK-Fc: a therapeutic antagonist for RANK-L in myeloma. 2003 Cancer pmid:12548579
Oyajobi BO and Mundy GR Receptor activator of NF-kappaB ligand, macrophage inflammatory protein-1alpha, and the proteasome: novel therapeutic targets in myeloma. 2003 Cancer pmid:12548580
Croucher PI et al. Bisphosphonates and osteoprotegerin as inhibitors of myeloma bone disease. 2003 Cancer pmid:12548581
Lipton A Bisphosphonates and metastatic breast carcinoma. 2003 Cancer pmid:12548585
Demers LM Bone markers in the management of patients with skeletal metastases. 2003 Cancer pmid:12548589
Body JJ et al. A phase I study of AMGN-0007, a recombinant osteoprotegerin construct, in patients with multiple myeloma or breast carcinoma related bone metastases. 2003 Cancer pmid:12548591
Liu JZ et al. [The OPG/RANKL/RANK system and bone resorptive disease]. 2003 Sheng Wu Gong Cheng Xue Bao pmid:15971575
Liu JZ et al. [Construction and biological activity study of human osteoprotegerin expressing adenoviral system]. 2003 Sheng Wu Gong Cheng Xue Bao pmid:15969033
Elhasid R et al. Familial severe congenital neutropenia associated with infantile osteoporosis: a new entity. 2003 Am. J. Hematol. pmid:12508266
Haynes DR et al. Osteoprotegerin expression in synovial tissue from patients with rheumatoid arthritis, spondyloarthropathies and osteoarthritis and normal controls. 2003 Rheumatology (Oxford) pmid:12509625

Table of Content